Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41470   clinical trials with a EudraCT protocol, of which   6815   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-002088-25
    Sponsor's Protocol Code Number:N-003-CRD003
    National Competent Authority:Austria - BASG
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2019-07-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedAustria - BASG
    A.2EudraCT number2018-002088-25
    A.3Full title of the trial
    A Phase II, Single-arm, Open-Label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients with Decompensated Cirrhosis
    Estudio de fase II, de un brazo, abierto para caracterizar el efecto en la presión portal, en la función renal y el perfil farmacocinético de N-003 en pacientes con cirrosis descompensada.
    Eine einarmige, offene Phase-II-Studie zur Charakterisierung des Einflusses auf den portalen Druck, die Nierenfunktion und das pharmakokinetische Profil von N-003 bei Patienten mit dekompensierter Zirrhose
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Non-Placebo Clinical Trial in Patients with Chronic Liver Disease to Test the Safety and Effect of N-003 on Liver Blood Pressure and Renal Function, as well as N-003 Levels in Blood

    Ensayo clínico no controlado con placebo en pacientes con enfermedad hepática grave para probar la seguridad y el efecto de N-003 en la presión sanguínea hepática y en la función renal así como los niveles de N-003 en sangre
    Eine klinische Studie ohne Placebo bei Patienten mit chronischer Lebererkrankung zur Prüfung der Sicherheit und Wirkung von N-003 auf Leberblutdruck und Nierenfunktion, sowie den N-003-Spiegel im Blut
    A.4.1Sponsor's protocol code numberN-003-CRD003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNoorik Biopharmaceuticals AG
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNoorik Biopharmaceuticals AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNoorik Biopharmaceuticals AG
    B.5.2Functional name of contact pointCEO
    B.5.3 Address:
    B.5.3.1Street AddressLange Gasse 15
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4052
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number4176 398 70 07
    B.5.6E-mailiker.navarro@noorik.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameN-003 (ambrisentan) 5 mg/ml solution subcutaneous administration
    D.3.2Product code N-003
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAMBRISENTAN
    D.3.9.1CAS number 177036-94-1
    D.3.9.4EV Substance CodeSUB25424
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameN-003 (ambrisentan) 5 mg/ml solution for oral administration
    D.3.2Product code N-003
    D.3.4Pharmaceutical form Oral drops, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAMBRISENTAN
    D.3.9.1CAS number 177036-94-1
    D.3.9.4EV Substance CodeSUB25424
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    decompensated liver cirrhosis
    cirrosis hepática descompensada
    Dekompensierte Leberzirrhose
    E.1.1.1Medical condition in easily understood language
    chronic liver disease with major complications:
    - water in the belly (ascites)
    - bleeding from stomach or oesophagus (variceal bleeding)
    - disturbance of consciousness (hepatic encephalopathy)
    enfermedad hepática crónica con complicaciones graves
    -agua en el abdomen(ascitis)
    -sangrado del estómago o del esófago(sangrado de varices)
    -alteración de las consciencia(encefalopatía hepática)
    Chronische Lebererkrankung mit schweren Komplikationen:
    - Bauchwassersucht (Aszites)
    - Krampfadern in der Speiseröhre
    - Bewusstseinsstörungen (hepatische Enzephalopathie)
    E.1.1.2Therapeutic area Body processes [G] - Metabolic Phenomena [G03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10064704
    E.1.2Term Decompensated cirrhosis
    E.1.2System Organ Class 100000004871
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to determine whether N-003 reduces portal pressure in patients with decompensated cirrhosis and a history of recurrent ascites.
    El objetivo primario de este estudio es determinar si N-003 reduce la presión portal en pacientes con cirrosis hepática descompensada e historia recurrente de ascitis
    Das primäre Ziel der Studie ist es festzustellen, ob N-003 den Portaldruck bei Patienten mit dekompensierter Zirrhose und rezidivierendem Aszites reduziert.
    E.2.2Secondary objectives of the trial
    •the effect of N-003 on weight
    •the effect of N-003 on abdominal girth
    •the effect of N-003 on liver disease severity scores (MELD and Child-Pugh scores)
    •the effect of N-003 on cardiac and pulmonary haemodynamics
    •the pharmacokinetic profile of N-003 in patients with liver impairment
    •the effect of N-003 on plasma endothelin
    •to assess the safety and tolerability of N-003 in this population
    •El efecto de N-003 en el peso
    •El efecto de N-003 en el perímetro abdominal.
    •El efecto de N-003 en los índices de severidad de enfermedad hepática (índices MELD y Child-Pugh).
    •El efecto de N-003 en la hemodinamia cardiaca y pulmonar.
    •El perfil farmacocinético de N-003 en pacientes con fallo hepático.
    •El efecto de N-003 en la endotelina plasmática.
    •Evaluar la seguridad y tolerabilidad de N-003 en esta población
    • die Wirkung von N-003 auf das Gewicht
    • die Wirkung von N-003 auf den Bauchumfang
    • die Wirkung von N-003 auf den Schweregrad der Lebererkrankung (MELD- und Child-Pugh-Scores)
    • die Wirkung von N-003 auf die Herz- und Lungenhämodynamik
    • das pharmakokinetische Profil von N-003 bei Patienten mit Leberschädigung
    • die Wirkung von N-003 auf Plasma-Endothelin
    • Bewertung der Sicherheit und Verträglichkeit von N-003 in dieser Population
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Signed informed consent including data protection declaration prior to study participation
    2.Subjects with confirmed cirrhosis (by biopsy, ultrasound, and/or laboratory examinations)
    3.Ascites Grade II or Grade III at screening
    4.Currently treated with at least one diuretic or the subject is considered intolerant to diuretics in the investigator’s opinion
    1.Firma del consentimiento informado, incluyendo una declaración de la protección de datos antes de la participación en el estudio.
    2.Sujetos con cirrosis confirmada (mediante biopsia, ultrasonidos, y/o pruebas de laboratorio).
    3.Ascitis de Grado II y Grado III en la selección.
    4.Tratamiento actual con al menos un diurético o que el sujeto se considere intolerante a los diuréticos a juicio del investigador.
    1.Unterzeichnete Einwilligungserklärung inklusive Datenschutzerklärung vor der Studienteilnahme
    2.Personen mit bestätigter Zirrhose (durch Biopsie, Ultraschall und/oder Laboruntersuchungen)
    3.Aszites Grad II oder Grad III beim Screening
    4.Derzeit mit mindestens einem Diuretikum behandelt oder der Teilnehmer gilt nach Ansicht des Prüfers als intolerant gegenüber Diuretika
    E.4Principal exclusion criteria
    1.Age <18 years of age
    2.Any of the following laboratory findings at the time of screening
    a.Serum creatinine level >1.5mg/dL (>132 µmol/L)
    b.Serum Na+ < 125 meq/L
    c.Serum K+ ≥ 5.5 meq/L
    d.Serum bilirubin ≥ 5 mg/dL (85.5 µmol/L)
    e.INR >3.0
    3.Women of childbearing potential with no effective contraceptive method (women of childbearing potential [pre-menopausal, not surgically sterile for at least 3 months prior to the time of screening] must have a confirmed negative serum β-hCG pregnancy test prior to enrolment and at Baseline Visit. They must use an effective contraceptive method throughout the study, and agree to repeat serum β-hCG pregnancy tests at designated visits)
    4.Pregnancy or lactation
    5.Systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg
    6.Sepsis and/or uncontrolled bacterial infection
    7.Current or recent documented nephrotoxicity (within 4 weeks)
    8.Hepatic Encephalopathy above grade 1
    9.History of variceal bleeding in the last 2 months
    10.Suspicion of active alcohol consumption in the last 3 months
    11.History of liver or kidney transplantation
    12.History of Transjugular Intrahepatic Portosystemic Shunt (TIPS)
    13.Suspected occlusive portal vein or splenic vein thrombosis
    14.Hepatocellular carcinoma (HCC) beyond the Milan criteria
    15.Acute Liver Failure or superimposed acute liver injury due to drugs (e.g., acetaminophen), dietary supplements, herbal preparations, viral hepatitis, or toxins
    16.Severe cardiovascular disease, including, but not limited to, unstable angina, pulmonary oedema, congestive heart failure
    17.Current or recent (within 30 days) renal replacement therapy (RRT)
    18.If on beta-blockers, a change in dose or drug within last 15 days prior to screening
    19.Use of any other endothelin receptor antagonist, octreotide, midodrine, terlipressin in last 15 days prior to screening
    20.Known hypersensitivity to contrast-media
    21.Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at the time of screening that in the judgment of the investigator or any sub-investigator would preclude safe completion of the study or constrains the assessment of efficacy
    22.Known sensitivity to ambrisentan or any of the excipients of the formulation
    23.Participation in other clinical research involving investigational medicinal products within 30 days of enrolment
    24.Subjects who have difficulties in understanding the language in which the study information is given
    25.Subjects who do not agree to the transmission of their anonymous data within the liability of documentation and notification
    26.Staff of the study centre, staff of the sponsor or CRO, the investigator himself or close relatives of the investigator.

    Cardiac and Pulmonary Haemodynamic Study exclusion Criteria: For subjects enrolled in sites performing cardiac and pulmonary catheterisations, subjects fulfilling any of the exclusion criteria below may participate in the study, but will not undergo cardiac and pulmonary catheterisation:
    1.Significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate < 45 beats per minute or atrial fibrillation/flutter with sustained ventricular response of > 90 beats per minute at rest, or Long QT syndrome or QTc > 450 ms
    2.Significant left ventricular outflow tract obstructions (e.g., severe valvular aortic stenosis, obstructive cardiomyopathy), severe mitral stenosis, restrictive amyloid myocardiopathy, acute myocarditis
    3.Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated
    4.Major neurologic event including cerebrovascular events, within 30 days prior to screening
    5.Clinical evidence of acute coronary syndrome currently or within 30 days prior to screening
    6.Permanent pacemaker, cardiac resynchronisation device or implantable cardioverter-defibrillator in situ.
    1.Edad <18 años.
    2.Alguno de los siguientes hallazgos de laboratorio en el momento de la selección:
    a.Nivel de creatinina sérica >1.5mg/dL (>132 µmol/L)
    b.Na+ sérico< 125 meq/L
    c.K+ sérico ≥ 5.5 meq/L
    d.Bilirrubina sérica ≥ 5 mg/dL (85.5 µmol/L)
    e.INR >3.0
    3.Mujeres en edad fértil con un método anticonceptivo no eficaz (las mujeres en edad fértil [premenopáusicas, no esterilizadas quirúrgicamente al menos 3 meses antes de la Visita de Selección] deben confirmar que no están embarazadas mediante una prueba de β-hCG en suero antes de la inclusión en el estudio y en la visita basal. Deben usar un método anticonceptivo eficaz durante el estudio, y aceptar realizarse la prueba de embarazo de β-hCG en suero en las visitas designadas).
    4. Embarazo o lactancia.
    5.Tensión sistólica <90 mmHg o tensión diastólica <60 mmHg.
    6.Sepsis y/o infección bacteriana no controlada.
    7.Nefrotoxicidad documentada actual o reciente (en las 4 semanas anteriores).
    8.Encefalopatía hepática mayor de grado 1.
    9.Historia de sangrado de las varices en los dos últimos meses.
    10.Sospecha de consumo de alcohol activo durante los últimos tres meses.
    11.Historia de trasplante hepático o renal.
    12.Historia de desvío portosistémico intrahepático transyugular (DPIT).
    13.Sospecha de trombosis oclusiva de la vena porta o de la vena esplénica.
    14.Carcinoma hepatocelular según el criterio Milan.
    15.Fallo hepático agudo o daño hepático superpuesto inducido por fármacos (ej. paracetamol), suplementos dietéticos, preparaciones de hierbas, hepatitis vírica y/o toxinas.
    16.Enfermedad cardiovascular severa, incluyendo, pero no únicamente, angina inestable, edema pulmonar y/o fallo cardíaco congestivo.
    17.Terapia de reemplazo renal (RRT) actual o reciente (en los 30 días anteriores)
    18.En caso de betabloqueantes, un cambio de dosis o de fármaco en los últimos 15 días antes de la selección.
    19.Uso de algún otro antagonista de los receptores de endotelina, octreotido, midodrina, terlipresina en los últimos 15 días.
    20.Hipersensibilidad conocida a los medios de contraste.
    21.Anomalías clínicamente significativas en los resultados de la exploración física, de los análisis de laboratorio, en el ECG o en las constantes vitales en el momento de la selección que a juicio del investigador o del co-investigador puedan impedir la finalización del estudio de un modo seguro o puedan limitar la evaluación de la eficacia.
    22.Alergia conocida a ambrisentan o a cualquier excipiente de la formulación.
    23.Participación en cualquier ensayo clínico en los 30 días anteriores a la inclusión en el estudio.
    24.Sujetos con dificultades para entender el lenguaje en el que se da la información al sujeto.
    25.Sujetos que no accedan a la transmisión de sus datos anónimos en lo que respecta a las funciones de documentación y notificación.
    26.Personal del centro de estudio, del promotor o de la CRO, el propio investigador o familiares de este.

    Criterios de exclusión para el estudio de hemodinamia cardiaca y pulmonar: Para sujetos inscritos en sitios que realizan cateterismos cardíacos y pulmonares, los sujetos que cumplan alguno de los siguientes criterios de exclusión pueden participar en el estudio, pero no se les realizará el cateterismo cardiaco y pulmonar:
    1.Arritmias significativas, que incluyen: taquicardia ventricular sostenida, bradicardia con frecuencia ventricular sostenida de < 45 latidos por minuto o fibrilación/palpitación auricular con respuesta ventricular sostenida de > 90 latidos por minuto en descanso, o síndrome de QT largo o QTc > 450 ms.
    2.Obstrucción significativa del tracto de salida del ventrículo izquierdo (ej., estenosis valvular aórtica severa, cardiomiopatía obstructiva), estenosis mitral severa, miocardiopatía amiloide restrictiva y/o miocarditis aguda.
    3.Insuficiencia aortica severa o regurgitación mitral severa para las cuales está indicada la intervención quirúrgica o percutánea.
    4.Eventos neurológicos graves incluyendo eventos cerebrovasculares, en los 30 días anteriores a la selección.
    5.Evidencia clínica de síndrome agudo coronario en la actualidad o en los 30 días anteriores a la inclusión en el estudio.
    6.Marcapasos permanente, dispositivo de resincronización cardiaca y/o desfibrilador cardioversor implantable in situ.
    1. Alter <18 Jahre
    2. Jeder der folgenden Laborbefunde zum Zeitpunkt des Screenings
    a. Serumkreatinininspiegel >1,5mg/dL (>132 µmol/L)
    b. Serum Na+ < 125 meq/L
    c. Serum K+ ≥ 5,5 meq/L
    d. Serum-Bilirubin ≥ 5 mg/dL (85,5 µmol/L)
    e. INR >3,0
    3. Gebährfähige Frauen ohne wirksame Verhütungsmethode (Gebährfähige Frauen (prämenopausal, nicht chirurgisch steril für mindestens 3 Monate vor dem Zeitpunkt des Screenings) müssen vor Einschluss und bei der Baseline Visite einen negativen Serum β-hCG Schwangerschaftstest haben.
    4. Schwangerschaft oder Stillzeit
    5. Systolischer Blutdruck <90 mmHg oder diastolischer Blutdruck <60 mmHg
    6. Sepsis und/oder unkontrollierte bakterielle Infektion
    7. Aktuelle oder kürzlich dokumentierte Nephrotoxizität (innerhalb von 4 Wochen)
    8. Hepatische Enzephalopathie über Klasse 1
    9. Geschichte der Varizenblutung in den letzten 2 Monaten
    10. Verdacht auf aktiven Alkoholkonsum in den letzten 3 Monaten
    11. Geschichte der Leber- oder Nierentransplantation
    12. Geschichte des Transjugularen Intrahepatischen Portosystemischen Shunts (TIPS)
    13. Verdacht auf okklusive Pfortader oder Milzvenenthrombose
    14. Hepatozelluläres Karzinom (HCC) jenseits der Mailänder Kriterien
    15. Akutes Leberversagen oder überlagerte akute Leberschädigung durch Medikamente (z.B. Acetaminophen), Nahrungsergänzungsmittel, pflanzliche Präparate, virale Hepatitis oder Toxine
    16. Schwere Herz-Kreislauf-Erkrankungen, einschließlich, aber nicht beschränkt auf, instabile Angina, Lungenödem, kongestive Herzinsuffizienz
    17. Laufende oder vergangene (innerhalb von 30 Tagen) Nierenersatztherapie (RRT)
    18. Bei Beta-Blocker Einnahme, eine Änderung der Dosis oder des Medikaments innerhalb der letzten 15 Tage vor dem Screening
    19. Verwendung eines jedes anderen Endothelin-Rezeptor-Antagonisten, Octreotide, Midodrine, Terlipressin in den letzten 15 Tagen vor dem Screening
    20. Bekannte Überempfindlichkeit gegen Kontrastmittel
    21. Jede klinisch signifikante Anomalie, die bei der körperlichen Untersuchung, den Labortests, dem EKG oder den Vitalparametern zum Zeitpunkt der Untersuchung festgestellt wurde und die nach Auffassung des Prüfers oder eines Unterprüfers den sicheren Abschluss der Studie verhindern oder die Beurteilung der Wirksamkeit einschränken würde.
    22. Bekannte Empfindlichkeit gegenüber Ambrisentan oder einem der Hilfsstoffe der Formulierung
    23. Teilnahme an anderen klinischen Studien mit Prüfpräparaten innerhalb von 30 Tagen nach Einschluss
    24. Personen, die Schwierigkeiten haben, die Sprache zu verstehen, in der die Studieninformationen gegeben werden
    25. Personen, die mit der Übermittlung ihrer anonymen Daten im Rahmen der Dokumentations- und Benachrichtigungspflicht nicht einverstanden sind
    26. Mitarbeiter des Studienzentrums, Mitarbeiter des Sponsors oder des CRO, der Prüfer selbst oder enge Angehörige des Prüfers

    Ausschlusskriterien für kardiale und pulmonale hämodynamische Studien: Patienten, die in Zentren eingeschlossen sind, an denen Herz- und Lungenkatheteruntersuchungen durchgeführt werden, und eines der folgenden Ausschlusskriterien erfüllen, können an der Studie teilnehmen, werden jedoch nicht kardial und pulmonal katheterisiert:
    1. Signifikante Arrhythmien, zu denen eine der folgenden gehören: anhaltende ventrikuläre Tachykardie, Bradykardie mit anhaltender ventrikulärer Rate < 45 Schläge pro Minute oder Vorhofflimmern/Flattern mit anhaltender ventrikulärer Reaktion von > 90 Schlägen pro Minute in Ruhe, oder Long QT-Syndrom oder QTc > 450 ms.
    2. Signifikante linksventrikuläre Ausflussstörungen (z.B. schwere Klappen-Aortenstenose, obstruktive Kardiomyopathie), schwere Mitralstenose, restriktive Amyloidmyokarditis, akute Myokarditis
    3. Schwere Aorteninsuffizienz oder schwere Mitralinsuffizienz, für die ein chirurgischer oder perkutaner Eingriff indiziert ist.
    4. Neurologisches Großereignis, einschließlich zerebrovaskulärer Ereignisse, innerhalb von 30 Tagen vor dem Screening
    5. Klinischer Nachweis eines akuten Koronarsyndroms derzeit oder innerhalb von 30 Tagen vor dem Screening
    6. Permanenter Herzschrittmacher, Herzresynchronisationsgerät oder implantierbarer Kardioverter-Defibrillator in situ.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is defined as the mean change in Hepatic Vein Pressure Gradient (HVPG) from baseline to Day 14.
    La primera variable de eficacia se define como el cambio medio en el Gradiente de Presión Venosa Hepático (GPVH) entre el valor basal y el Día 14.
    Der primäre Wirksamkeitsendpunkt ist definiert als die mittlere Veränderung des Hepatischen Venendruckgradienten (HVPG) von der Basislinie bis zum Tag 14.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Visit 1 - day 1 & visit 2 - day 14
    Visita 1 - día 1 & visita 2 - día 14
    Visite 1 - Tag 1 & Visite 2 - Tag 14
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints include:
    •change in weight from baseline to each study visit
    •change in abdominal girth from baseline to each study visit
    •change in MELD score from baseline to each study visit
    •change in Child-Pugh score from baseline to each study visit
    •change in cardiac and pulmonary haemodynamic variables from baseline to 90 minutes post-drug administration, Day 14 (trough) and 90 minutes after last dose (Day 14). (evaluated only at investigational sites that perform cardiac and pulmonary catheterisation)
    •Cambio del peso entre el valor basal y en cada visita de estudio.
    •Cambio del perímetro abdominal entre el valor basal y en cada visita de estudio
    •Cambio en la puntuación MELD entre el valor basal y en cada visita de estudio
    •Cambio en la puntuación Child-Pugh entre el valor basal y en cada visita de estudio
    •Cambio en las variables hemodinámicas cardíacas y pulmonares entre el valor basal y 90 minutos tras la administración el Día 1, Día 14 (medida valle) y 90 minutos tras la última dosis (Día 14).(evaluado solo en sitios de investigación que realizan cateterismo cardíaco y pulmonar)
    • Gewichtsänderung von der Baseline zu jeder Visite
    • Veränderung des Bauchumfangs von der Baseline bis zu jeder Visite
    • Veränderung des MELD-Scores von der Baseline zu jeder Visite
    • Änderung des Child-Pugh-Scores von der Baseline zu jeder Visite
    • Veränderung der kardialen und pulmonalen hämodynamischen Variablen von der Baseline zu, 90 Minuten nach der Verabreichung, Tag 14 (Talspiegel) und 90 Minuten nach der letzten Dosis (Tag 14). (wird nur an Zentren evaluiert, die Herz- und Lungenkatheteruntersuchungen durchführen).
    E.5.2.1Timepoint(s) of evaluation of this end point
    at all visits starting from baseline
    en todas las visitas desde la visita basal
    bei allen Visiten ab der Baseline Visite
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last patient last visit
    última visita del último paciente
    Letzter Patient letzte Visite
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months21
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months21
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 12
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 12
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 24
    F.4.2.2In the whole clinical trial 24
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-07-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-05-03
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2021-01-20
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA